



SDAI LIMITED
(Company Registration No. 201107179D)
(Incorporated in the Republic of Singapore)

ENTRY INTO COOPERATION AGREEMENT

1. INTRODUCTION

The board of directors (the “**Board**” or “**Directors**”) of SDAI Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”) wishes to refer to the Company’s announcement dated 12 August 2025 in relation to the strategic cooperation agreement entered into between the Company and LiveBeyond Pte. Ltd. (“**Consultant**”). Further to the strategic cooperation agreement entered on 12 August 2025, the Company is pleased to announce that its wholly-owned subsidiary, SDAI Healthcare Pte. Ltd. (“**SDAI Healthcare**”), has, on 8 May 2026, entered into a Cooperation Agreement (“**Cooperation Agreement**”) with the Consultant.

Pursuant to the Cooperation Agreement, the Consultant will provide strategic and scientific consultancy services to support the Group’s commercialisation of longevity-related products supplied by a nominated supplier (“**Supplier**”) and any product reformulation, upgrade, derivative, variant or successor product of the foregoing (“**Products**”) including, *inter alia*, the alpha-ketoglutarate (“**AKG**”) products, as well as providing scientific advisory and market credibility endorsement for the Products.

2. INFORMATION ON LIVEBEYOND PTE. LTD.

- 2.1. The Consultant is a Singapore-incorporated company specializing in longevity research and medical solutions. The Consultant provides access to cutting-edge scientific expertise, including world-renowned longevity experts Dr Brian Kennedy and Dr Chong He.

3. RATIONALE FOR THE AGREEMENT

Following the approval from shareholders of the Company (“**Shareholders**”) for the diversification of the Group’s core business into the biotechnology business at the Company’s extraordinary general meeting held on 30 April 2026, the entry into the Cooperation Agreement forms part of the Group’s strategy to support the Group’s commercialisation of longevity and anti-ageing products including, *inter alia*, AKG-based products, through access to specialised scientific expertise and market credibility.

4. SALIENT TERMS OF THE AGREEMENT

4.1. Scope of services

The Consultant will provide the following services to the client: (a) technology and formula sourcing; (b) scientific validation and advisory; (c) strategic and market enablement; (d) support for future collaboration development with the Supplier; (e) future collaboration development; and

(f) additional advisory (collectively, the “**Services**”).

4.2. **Endorsement**

The Consultant will provide scientific credibility endorsement exclusively for the AKG-related products manufactured by the Supplier on behalf of SDAI Healthcare within China, Singapore and any other markets as may be agreed between the Consultant and SDAI Healthcare (the “**Territories**”).

4.3. **Term**

The Cooperation Agreement shall take effect from the date of the supplier agreement to be entered into between SDAI Healthcare and the Supplier (“**Supplier Agreement**”) and will remain in force for as long as the commercial collaboration between SDAI Healthcare and the Supplier relating to products supplied by the Supplier continues.

4.4. **Fees**

In consideration for the Services, SDAI Healthcare shall pay an annual fee comprising of an amount based on a percentage of annual net revenue received by SDAI Healthcare from the sale and distribution of the Products in the Territories (“**Percentage Fee Structure**”), subject to a fixed minimum amount, whichever is higher and reimbursement of agreed operating expenses incurred in connection with the provision of the Services. The Percentage Fee Structure is subject to a phased ramp-up over the initial years of the Cooperation Agreement, in line with the anticipated scale-up of commercial activities. The first instalment shall be due within 30 days of the formal execution date of the Supplier Agreement.

5. **FINANCIAL EFFECTS**

Until the formal execution of the Supplier Agreement and without assumption of any commercialisation arising from the Cooperation Agreement, the entry into the Cooperation Agreement is not expected to have any material impact on the net tangible assets and earnings per share of the Group for the financial year ending 31 December 2026.

6. **INTERESTS OF DIRECTORS AND SUBSTANTIAL SHAREHOLDERS**

None of the Directors or substantial Shareholders, nor their respective associates, have any interest, direct or indirect, in the Cooperation Agreement, other than through their respective shareholdings in the Company.

7. **DOCUMENT AVAILABLE FOR INSPECTION**

A copy of the Cooperation Agreement is available for inspection at the Company’s registered office at 6 Clementi Loop, #02-18, EAC Building, Singapore 129814, during normal business hours for a period of three (3) months from the date of this announcement.

8. **CAUTIONARY STATEMENT**

The shares of the Company have been suspended from trading on the Singapore Exchange Securities Trading Limited since 12 July 2021. Shareholders and potential investors of the Company are advised to read this announcement and any further announcements by the Company carefully. Shareholders and potential investors of the Company who are in doubt as to the action they should take should consult their stockbrokers, bank managers, solicitors, accountants, or other professional advisers.

There is no certainty or assurance that the commercial objectives of the Agreement will be fully realized or that the formal Supplier Agreement will be executed on the terms currently contemplated.

The Company will make further announcements as and when there are material development(s) in relation to the Cooperation Agreement and/or the Supplier Agreement.

By Order of the Board of
SDAI Limited

Mdm Hao Dongting
Executive Chairperson
8 May 2026

This announcement has been reviewed by the Company's sponsor, ZICO Capital Pte. Ltd. (the "Sponsor").

This announcement has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "SGX-ST") and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Ms Yang Zhenni, ZICO Capital Pte. Ltd. at 77 Robinson Road, #06-03 Robinson 77, Singapore 068896, telephone (65) 6636 4201.